- Investigators
- Benjamin T Alwood, Scott L Silliman
- Ages
- 18 Years - 90 Years
- Sexes
- All
Clinical trials
-
ReMEDy2: A Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke -
ReMEDy2: A Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke - Investigators
- Benjamin T Alwood, Scott L Silliman
- Ages
- 18 Years - 90 Years
- Sexes
- All